A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases - PubMed (original) (raw)

Comparative Study

A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases

H Tsuda et al. Breast Cancer Res Treat. 1998 Mar.

Abstract

In 150 surgically resected primary breast carcinomas that had axillary lymph-node metastases, we examined the incidence of loss of heterozygosity on chromosomes 16p, 16q, 17p, 17q, and 18q, point mutation of the p53 tumor-suppressor gene, nuclear immunoreaction of p53 protein, and amplifications of the c-erbB-2 and int-2 oncogenes by Southern blotting, single-strand conformation polymorphism analysis, and immunohistochemistry. We analyzed the association of these factors and conventional prognostic parameters with outcome of the patients, using Cox's univariate and multivariate analyses. The univariate analysis revealed that nuclear p53 immunoreaction, p53 mutation, and c-erbB-2 amplification as well as the number of metastatic lymph nodes, histological grade, and hormone-receptor statuses were significant prognostic indicators for both recurrence and cancer death. p53 immunoreaction was correlated more strongly with a poor prognosis than p53 mutations. The combination of p53 and c-erbB-2 effectively identified the high-risk patient group, and even among Grade 3 cases the subgroup with these alterations tended to have poorer clinical outcomes. The multivariate analysis including p53, c-erbB-2, and conventional factors. Lymph node status, grade, and p53 had independent impacts on the survival of patients. Under identical adjuvant systemic therapies, prognoses differed between the patient groups with and without alterations of p53 or c-erbB-2. Appropriate combinations of conventional factors with nuclear p53 immunoreaction and c-erbB-2 amplification would help to identify highly aggressive node-positive breast carcinomas and would aid stratification of patient groups in randomized clinical trials of adjuvant systemic therapies.

PubMed Disclaimer

Cited by

Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.
Huang GC, Hobbs S, Walton M, Epstein RJ. Huang GC, et al. Br J Cancer. 2002 Apr 8;86(7):1104-9. doi: 10.1038/sj.bjc.6600219. Br J Cancer. 2002. PMID: 11953857 Free PMC article.
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.
Pharoah PD, Day NE, Caldas C. Pharoah PD, et al. Br J Cancer. 1999 Aug;80(12):1968-73. doi: 10.1038/sj.bjc.6690628. Br J Cancer. 1999. PMID: 10471047 Free PMC article.
Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI. Beenken SW, et al. Ann Surg. 2001 May;233(5):630-8. doi: 10.1097/00000658-200105000-00006. Ann Surg. 2001. PMID: 11323501 Free PMC article. Clinical Trial.
Identification of high-risk breast cancer patients from genetic changes of their tumors.
Watatani M, Inui H, Nagayama K, Imanishi Y, Nishimura K, Hashimoto Y, Yamauchi E, Hojo T, Kotsuma Y, Yamato M, Matsunami N, Yasutomi M. Watatani M, et al. Surg Today. 2000;30(6):516-22. doi: 10.1007/s005950070118. Surg Today. 2000. PMID: 10883462
Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H. Yamashita H, et al. Breast Cancer Res. 2004;6(1):R24-30. doi: 10.1186/bcr738. Epub 2003 Nov 7. Breast Cancer Res. 2004. PMID: 14680497 Free PMC article.

A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases - PubMed (original) (raw)